Proton Therapy Market Expected to Reach $1.6 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Proton Therapy Market," The proton therapy market size was $438.33 million in 2021, and is estimated to reach $1.6 billion by 2031, growing at a CAGR of 13.65% from 2022 to 2031.

Proton therapy, also known as proton radiotherapy and proton beam therapy, involves radiation devices with protons as a source of radiation. Proton therapy is used to kill cancer cells. In proton therapy particle accelerators are used to target the tumors with a beam of protons. Protons are charged particles that interfere with DNA of cells, thus damaging them leading to cell death. Proton therapy devices are costly, space consuming equipment that comprises accelerators, electro-magnets, gantries, nozzles, and patient rooms.

Increase in prevalence of cancer, surge in number of awareness campaigns about benefits of proton therapy, and technological advancements in proton therapy devices are the key proton therapy market trends. In addition, patients are eager to know more about proton therapy treatment process and growth of global recognition of proton therapy and its benefits further drive the market growth. However, high cost of proton therapy and large size of these devices, requiring dedicated areas, are anticipated to hamper the market growth. Conversely, introduction of proton therapy in emerging economies is expected to offer lucrative growth opportunities for key players in the market.

On the basis of indications, the proton therapy market is categorized into head & neck cancer, central nervous system cancer, prostate cancer, breast cancer and others. The central nervous system cancer segment is expected to dominate the market during the forecast period, owing to increase in prevalence of CNS cancer and rise in preference for advance therapies by healthcare professionals.

Depending on product type, the accelerator segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increase in prevalence of cancer, cost advantage as compared to outsourced radioactive tracers and availability of technologically advanced diagnostic devices further boost proton therapy market growth.

On the basis of end user, the hospital segment held the largest proton therapy market share in 2021, and is expected to continue this trend during the forecast period, owing to increase in prevalence of cancer, development in healthcare for infrastructure of hospitals, high tech equipment, and self-awareness about diseases.

North America accounted for the largest market share in 2021, and is expected to remain dominant during the forecast period. This was attributed to well-established healthcare system, increase in number of geriatric patients, and supportive reimbursement policies in healthcare system and increase in number of healthcare facilities offering proton therapy. Asia-Pacific is projected to register the highest CAGR of 14.95% during the forecast period. Improving healthcare infrastructure in the region and large patient populations for target diseases. In addition, expanding presence of key market players in the region propel the market growth.

Major companies profiled in proton therapy industry report include Hitachi, Ltd., Ion Beam Applications S.A., Mevion Medical Systems, Mirion Technologies Ltd., Optivus Proton Therapy, Inc., Provision Healthcare, Pro Tom International, Siemens, Sumitomo Heavy Industries, Ltd., and Toshiba Corporation.

KEY FINDINGS OF STUDY

• On the basis of indication, the CNS cancer segment is estimated to register CAGR of 12.41% from 2022 to 2031.
• On the basis of product type, the accelerator segment is estimated to register CAGR of 13.21% from 2022 to 2031.
• By end user, the hospital segment is anticipated to register CAGR of 13.8% from 2022–2031
• By region, Asia-Pacific is expected grow at the highest CAGR of 14.95% from 2022 to 2031.